Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490086 · ClinicalTrials.gov registry record · Phase 2
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 2 study, sponsored by Reviva Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT01490086: Completed Phase 2 study, sponsored by Reviva Pharmaceuticals.
NCT01490086 is a Phase 2 study that has completed, run by Reviva Pharmaceuticals. The registered enrollment target is 234 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01490086, a Phase 2 study, has completed, sponsored by Reviva Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
Primary Outcome
PANSS total score comprises Positive (Delusions, Conceptual disorganization, Hallucinatory behavior, Excitement, Grandiosity, Suspiciousness/persecution, Hostility), Negative (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking), and General Psychopathology (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardati
Interventions
- DRUG placebo
- DRUG aripiprazole
- DRUG RP5063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT01490086 record still lists
NCT01490086 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01490086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01490086 about?
NCT01490086 is a clinical study titled "RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder". The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
What is the current status of trial NCT01490086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2011-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01490086?
The interventions under investigation include: placebo (DRUG), aripiprazole (DRUG), RP5063 (DRUG).
Who is sponsoring clinical trial NCT01490086?
This trial is sponsored by Reviva Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01490086's enrollment target sits among peer trials
234 255th of 2000 higher than 1,745 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia